Cargando…
Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
Autores principales: | Laszlo, George S., Alonzo, Todd A., Gudgeon, Chelsea J., Harrington, Kimberly H., Kentsis, Alex, Gerbing, Robert B., Wang, Yi-Cheng, Ries, Rhonda E., Raimondi, Susana C., Hirsch, Betsy A., Gamis, Alan S., Meshinchi, Soheil, Walter, Roland B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129595/ https://www.ncbi.nlm.nih.gov/pubmed/27903291 http://dx.doi.org/10.1186/s13045-016-0364-0 |
Ejemplares similares
-
High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group
por: Laszlo, George S., et al.
Publicado: (2015) -
Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children’s Oncology Group protocol AAML0531
por: Voigt, Andrew P., et al.
Publicado: (2017) -
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group
por: Aplenc, Richard, et al.
Publicado: (2020) -
Ethnic Variation of TET2 SNP rs2454206 and Association with Clinical Outcome in Childhood AML: A Report from the Children’s Oncology Group
por: Kutny, Matthew A., et al.
Publicado: (2015) -
Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia
por: Laszlo, George S., et al.
Publicado: (2016)